RBR-9xmfyq已完成未知
Evaluation of different doses of botulinum toxin type A for the treatment of gingival smile
Centro Brasileiro de Estudos em Dermatologia0 个研究点开始时间: 2020年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 70Y（—）
入选标准
- •Individuals aged between 18 and 70 years;
- •Superior anterior gingival exposure: more than 4 mm, for subjects included in group A and 2 to 4 mm, for subjects included in group B;
- •Presence of at least one indication for cosmetic treatment with botulinum toxin in the upper face;
- •Medical history and physical examination that, in the opinion of the investigator, does not interfere with the progress of the study;
- •Women of childbearing potential should have a negative urinary pregnancy test at visit 1. These subjects should use a highly effective contraception method during the study: combined oral contraceptives [estrogen and progesterone] or implanted contraceptives (with a stable dose for at least 1 month prior to study entry), bilateral tubal ligation, hormonal intrauterine device (inserted at least 1 month prior to study entry), strict abstinence (at least 1 month prior to entry into the study and agree to continue for the duration of the study), or vasectomized partner (at least 3 months prior to study entry) or use of condom;
- •Women presenting for childbearing potential (e.g. before menstruation, post menopause (absence of menstrual bleeding for 1 year before entry into the study), hysterectomy, or bilateral ovariectomy, less than one year postmenopausal);
- •Willingness to comply with protocol requirements and study duration.
- •Understanding and signing the Informed Consent Term (ICF) at baseline, before any study procedure is performed.
排除标准
- •Pregnant and/or breastfeeding women, or women who wish to become pregnant during the study period;
- •Any surgical intervention that has affected the area evaluated in this study;
- •Any cosmetic procedures, including fillers, or scars that may interfere with the results of the study;
- •Previous treatment with botulinum toxin for gingival smile less than 6 months ago, or for other indications on the face less than 12 months ago;
- •Evident facial asymmetry;
- •Active inflammation or infections in the treated areas;
- •Neoplastic, muscle or neurological diseases (e.g. Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and motor neuron disease);
- •Serious psychiatric disorders;
- •Any other disease or chronic or serious decompensated medical condition that, in the opinion of the investigator, may interfere with the assessments or participation in the study or put subject at significant risk;
- •History of sensitivity to the formula components;
- •Current use of aminoglycoside antibiotics or penicillamines, quinines or calcium channel blockers or use at any time during the study;
- •Coagulation disorders or use of anticoagulants;
- •Vulnerable subjects (such as those deprived of their liberty) as defined in Section 1.61 of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) for Good Clinical Practice (GCP);
- •Subjects with history of non-adherence to medications or showing difficulties to adhere to the study protocol;
- •Current participation in another drug or device clinical study OR participation within 30 days prior to Day 1 OR in a period of exclusion from a previous clinical study.
研究者
相似试验
Enrolling By Invitation
4 期
Efficacy and optimized dosage of botulinum toxin type A injection for treatment of Acne vulgaris, enlarged pore, and oiliness: A randomized placebo-controlled trialPatients with moderate acne vulgarisBotulinum toxin type A, acne vulgaris, enlarged pore, oilinessTCTR20231025002Srinakharinwirot University75
招募中
3 期
A Comparative Study of 2 doses of Botulinum Toxin A in Post Traumatic Trigeminal Neuropathic PaiPost Traumatic Trigeminal Neuropathic Pain (PTTNP)Botulinum Toxin APost Traumatic Trigeminal Neuropathic PainOrofacial PainNeuropathic painTCTR20210811001euroscience Research and Development Group, Khon Kaen University46
招募中
2 期
Evaluation of the effectiveness of botulinum toxin in preventing hypertrophic scarringHypertrophic scarIRCT20100314003566N15Tabriz University of Medical Sciences30
已完成
1 期
The effect of botulinum toxin type A on reducing salivation and quality of life in patients with cerebral palsyCerebral palsy.Cerebral palsyIRCT20220516054868N1Esfahan University of Medical Sciences30
招募中
2 期
A comparison of the efficacy of botulinum toxin type A induced protective ptosis and temporary tarsorrhaphy in persistent corneal epithelial defect conditions. (Pilot study)Is the efficacy of botulinum toxin type A induced protective ptosis better than temporary tarsorrhaphy in persistent corneal epithelial defect?persistent epithelial defect,PED,botulinum toxin,tarsorrhaphy,corneal epithelial defectTCTR20130627002Ratchadapiseksompotch Research Fund11